PayerTalkCE Presents: Health Plan Strategies for Quality Improvement in Underserved Populations with Diabetes

Learn About:

Key steps taken by a Medicare Advantage plan to identify patient populations at greater risk for hypoglycemia
Quality improvement challenges and barriers to overcome for increased access and use of rtCGM

Expert Faculty Presenters:


	Estay Greene, PharmD Vice President of Pharmacy Zing Health Click here for biography

	Jeffrey Dunn, PharmD, MBA Chief Clinical Officer Cooperative Benefits Group (CBG) Click here for biography

Target Audience
This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
The true impact of diabetes-related severe hypoglycemia (SH) events is often underestimated by payers, with only approximately 5% of self-reported events among pharmacologically treated patients being captured by health care utilization-based surveillance. Racial/ethnic minority populations and other members affected by SDOH experience further worsening outcomes and resource utilization resulting from type 2 diabetes (T2D), necessitating specialized engagement and intervention. Continuous glucose monitoring (CGM) represents a significant advancement in the precision management of T2D, providing members with the ability to receive a virtually uninterrupted stream of information about the current physiology of their disease. However, many providers cite that prior authorizations delay treatment and negatively impact clinical outcomes. It is imperative to keep payers apprised of the latest innovations and benefits in rtCGM through timely outreach and clinical/payer expert educational offerings.

Educational Objectives
After completing this activity, the participant should be better able to:

Describe the risks of hypoglycemia in older patients with diabetes
Access health plan opportunities to identify underserved populations with diabetes, address the risks of hypoglycemia, and to implement appropriate interventions for prevention of hypoglycemia in high-risk populations
Identify steps for the delivery of successful quality improvement interventions in diabetes and the role of real-time continuous glucose monitoring

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.

UAN: JA0003680-9999-22-037-L01-P
Type of Activity: Knowledge

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Disclosure of Conflicts of Interest
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Working Group Members/Planners*	*Reported Financial Relationship*
Estay Greene, PharmD	Consulting Fees: Gilead, Sanofi Genzyme
Jeffrey Dunn, PharmD, MBA	Nothing to disclose

The MER planners and managers have nothing to disclose.
The Impact Education, LLC^® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.